Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway (Q38783325)

6 September 2017

title

Galectin-3 regulates metastatic capabilities and chemotherapy sensitivity in epithelial ovarian carcinoma via NF-κB pathway (English)

1 reference

6 September 2017

0 references

1 reference

Huaiwu Lu

1

1 reference

6 September 2017

Yunyun Liu

2

1 reference

6 September 2017

Dongyan Wang

3

1 reference

6 September 2017

Lijuan Wang

4

1 reference

6 September 2017

Hui Zhou

5

1 reference

6 September 2017

Guocai Xu

6

1 reference

6 September 2017

Lingling Xie

7

1 reference

6 September 2017

Miaofang Wu

8

1 reference

6 September 2017

Zhongqiu Lin

9

1 reference

6 September 2017

Yuefei Yu

10

1 reference

6 September 2017

Guorong Li

11

1 reference

6 September 2017

publication date

24 March 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

37

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

11469-11477

1 reference

Chemotherapy in advanced ovarian cancer

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

The HumanLGALS3(Galectin-3) Gene: Determination of the Gene Structure and Functional Characterization of the Promoter,

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Galectin-3 binding and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Transient gene silencing of galectin‐3 suppresses pancreatic cancer cell migration and invasion through degradation of β‐catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Gypenosides inhibits migration and invasion of human oral cancer SAS cells through the inhibition of matrix metalloproteinase-2 -9 and urokinase-plasminogen by ERK1/2 and NF-kappa B signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

CCL20/CCR6 promotes the invasion and migration of thyroid cancer cells via NF-kappa B signaling-induced MMP-3 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Activation of NF-kappaB by antineoplastic agents. Role of protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S13277-016-5004-3

Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer

21 January 2018

1 reference

12 December 2020

Saussurea lappa Clarke-Derived Costunolide Prevents TNF α -Induced Breast Cancer Cell Migration and Invasion by Inhibiting NF- κ B Activity

1 reference

12 December 2020

Synergistic effects of PectaSol-C modified citrus pectin an inhibitor of Galectin-3 and paclitaxel on apoptosis of human SKOV-3 ovarian cancer cells

1 reference

12 December 2020

Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes

1 reference

12 December 2020

Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB

1 reference

12 December 2020

Current diagnosis and treatment modalities for ovarian cancer

1 reference

12 December 2020

Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8.

1 reference

12 December 2020

New strategy for overcoming resistance to chemotherapy of ovarian cancer.

1 reference

12 December 2020

Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB.

1 reference

12 December 2020

Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family

1 reference

12 December 2020

10.1007/S13277-016-5004-3

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1008146601

0 references

1 reference